Strs Ohio Grows Stock Holdings in Tyra Biosciences, Inc. $TYRA

Strs Ohio boosted its holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 2,485.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,100 shares of the company’s stock after buying an additional 17,400 shares during the quarter. Strs Ohio’s holdings in Tyra Biosciences were worth $693,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Commodore Capital LP boosted its position in shares of Tyra Biosciences by 226.3% during the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock worth $29,667,000 after acquiring an additional 2,150,000 shares in the last quarter. Farallon Capital Management LLC lifted its stake in Tyra Biosciences by 80.7% during the fourth quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock worth $54,337,000 after purchasing an additional 923,000 shares during the last quarter. Caligan Partners LP boosted its holdings in Tyra Biosciences by 266.8% in the third quarter. Caligan Partners LP now owns 696,825 shares of the company’s stock valued at $9,749,000 after purchasing an additional 506,875 shares in the last quarter. Boone Capital Management LLC purchased a new position in Tyra Biosciences in the fourth quarter valued at approximately $10,476,000. Finally, Elmind Capital LP acquired a new stake in Tyra Biosciences during the fourth quarter worth approximately $9,202,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Guggenheim initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, April 14th. They set a “buy” rating and a $54.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Monday, April 20th. Wolfe Research initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, May 19th. They issued a “peer perform” rating for the company. Bank of America raised their price objective on Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $45.00 target price on shares of Tyra Biosciences in a research report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $47.00.

Tyra Biosciences Stock Up 2.0%

Shares of NASDAQ:TYRA opened at $32.57 on Thursday. The company has a market cap of $1.94 billion, a price-to-earnings ratio of -14.94 and a beta of 0.76. Tyra Biosciences, Inc. has a fifty-two week low of $9.93 and a fifty-two week high of $40.65. The firm’s 50-day simple moving average is $31.38 and its 200-day simple moving average is $32.10.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). On average, research analysts forecast that Tyra Biosciences, Inc. will post -2.68 EPS for the current year.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.